Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,282,357
  • Shares Outstanding, K 117,597
  • Annual Sales, $ 1,015 M
  • Annual Income, $ 444,090 K
  • EBIT $ 808 M
  • EBITDA $ 886 M
  • 60-Month Beta 0.94
  • Price/Sales 7.12
  • Price/Cash Flow 15.31
  • Price/Book 16.62

Options Overview Details

View History
  • Implied Volatility 31.79% (+0.60%)
  • Historical Volatility 27.95%
  • IV Percentile 4%
  • IV Rank 8.02%
  • IV High 59.09% on 04/04/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 30) 4.89 (6.82%)
  • Put/Call Vol Ratio 0.87
  • Today's Volume 562
  • Volume Avg (30-Day) 423
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 11,117
  • Open Int (30-Day) 12,222
  • Expected Range 66.76 to 76.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.84
  • Number of Estimates 4
  • High Estimate 1.95
  • Low Estimate 1.74
  • Prior Year 1.19
  • Growth Rate Est. (year over year) +54.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.36 +8.06%
on 12/22/25
75.59 -5.13%
on 01/07/26
+4.36 (+6.47%)
since 12/19/25
3-Month
61.22 +17.13%
on 12/11/25
75.59 -5.13%
on 01/07/26
+4.83 (+7.22%)
since 10/21/25
52-Week
47.50 +50.97%
on 05/14/25
79.50 -9.80%
on 09/23/25
+15.77 (+28.19%)
since 01/21/25

Most Recent Stories

More News
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

SAN DIEGO , Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30...

HALO : 71.71 (+1.82%)
Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

HALO : 71.71 (+1.82%)
1 Surging Stock Worth Investigating and 2 We Brush Off

1 Surging Stock Worth Investigating and 2 We Brush Off

MBLY : 10.88 (+3.42%)
SATS : 122.50 (+0.41%)
HALO : 71.71 (+1.82%)
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Agreement provides Takeda with exclusive access to ENHANZE ® drug delivery technology for vedolizumab

HALO : 71.71 (+1.82%)
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?

Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?

HALO : 71.71 (+1.82%)
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 1.1700 (+18.11%)
IDYA : 36.01 (+0.73%)
ZLAB : 18.84 (-0.37%)
CHRS : 1.6400 (+5.81%)
HALO : 71.71 (+1.82%)
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab

SKYE : 0.9806 (+0.79%)
HALO : 71.71 (+1.82%)
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration...

SKYE : 0.9806 (+0.79%)
HALO : 71.71 (+1.82%)
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025

Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025

HALO : 71.71 (+1.82%)
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

RYBREVANT FASPRO ™ is approved across all indications of RYBREVANT® (amivantamab-vmjw)

HALO : 71.71 (+1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 72.08
2nd Resistance Point 71.39
1st Resistance Point 70.91
Last Price 71.71
1st Support Level 69.74
2nd Support Level 69.05
3rd Support Level 68.57

See More

52-Week High 79.50
Last Price 71.71
Fibonacci 61.8% 67.28
Fibonacci 50% 63.50
Fibonacci 38.2% 59.72
52-Week Low 47.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar